CEPRA proposes TOXICOLOGICAL TEST according to GLP (Good Lab Practice) as required by REACH Regulation 1907/2006 or by GHS
Thanks to a national and international labs, CEPRA support the company to choose best testing strategy, the best lab and to evaluate results of studies
Principal TOXICOLOGICAL TEST / STUDIES:
ANNEX |
Number |
STUDY |
GUIDELINE |
| VII | 8.1 | Skin irritation / corrosion (in vitro) | OECD 431 – OECD 439 |
| VII | 8.2 | Eye irritation / corrosion (in vitro) | OECD 437 – OECD 492 |
| VII | 8.3 | Skin sensitization | OECD 429 OECD 406, EEC B.6 OECD 442 |
| VII | 8.4.1 | Bacterial reverse mutation test (Ames-test) | OECD 471- EEC B.13/ 14 |
| VIII | 8.4.2 | Cytogenetic testing in mammalian cells: Chromosome Aberration Test (in vitro) |
OECD 473 EEC B.10 |
| VIII | 8.4.2 | Micronucleus test (in vitro) | OECD 487 EEC B.10 |
| VIII | 8.4.3 | Gene mutation test in mammalian cells: Mouse Lymphoma Assay (in vitro) |
OECD 476 EEC B.17 |
| VII | 8.5.1 | Acute oral toxicity – Acute Toxic Class Method “ATC” – Fixed dose procedure – Up and down procedure |
OECD 423 OECD 420 OECD 425 |
| VIII | 8.5.2 | Acute inhalation toxicity | OECD 403 |
| VIII | 8.5.3 | Acute dermal toxicity | OECD 402, OECD 434 EEC B.3 |
| Repeated dose toxicity | OECD 40 -EEC B.7 OECD 410 OECD 412 OECD 408 – EEC B.26 OECD 411 OECD 413 OECD 452 |
||
| VIII | 8.8.1 | Assessment of the toxicokinetic behaviour | OECD 417 |